A combination of rilpivirine and any therapeutically equivalent form thereof protected by the basic patent, such as pharmaceutically acceptable addition salts of rilpivirine, including the hydrochloric acid salt of rilpivirine, and tenofovir, particularly the tenofovir fumarate disoproxil
This invention concerns HIV replication inhibitors of formula the N -oxides, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, wherein the ring containing -a 1 =a 2 -a 3 =a 4 - and -b 1 =b 2 -b 3 =b 4 - represents phenyl, pyridyl, pyrimidinyl, pirazinyl, pyridazinyl；n is 0 to 5； m is 1 to 4； R 1 is hydrogen； aryl； formyl； C 1-6 alkylcarbonyl； C 1-6 alkyl； C 1-6 alkyloxycarbonyl； substituted C 1-6 alkyl, C 1-6 alkylcarbonyl, C 1-6 alkyloxycarbonyl, C 1-6 alkylcarbonyloxy； substituted C 1-6 alkyloxyC 1-6 alkylcarbonyl； R 2 is hydroxy, halo, optionally substituted C 1-6 alkyl, C 3-7 cycloalkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, C 1-6 alkyloxy, C 1-6 alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono-or di(C 1-6 alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, - S(=O) p R 6 , -NH-S(=O) p R 6 , -C(=O)R 6 , -NHC(=O)H, -C(=O)NHNH 2 , -NHC(=O)R 6 -C(=NH)R 6 or a 5-membered heterocycle； X 1 is -NR 5 -, -NH-NH-, -N=N-, -O-, -C(=O)-, C 1-4 alkanediyl, -CHOH-, -S-, -S(=O) p -, -X 2 -C 1-4 alkanediyl- or -C 1-4 alkanediyl-X 2 -； R 3 is NHR 13 ； NR 13 R 14 ； -C(=O)-NHR 13 ； -C(=O)-NR 13 R 14 ； -C(=O)-R 15 ； -CH=N-NH-C(=O)-R 16 ； substituted C 1-6 alkyl； optionally substituted C 1-6 alkyloxyC 1-6 alkyl； substituted C 2-6 alkenyl； substituted C 2-6 alkynyl； C 1-6 alkyl substituted with hydroxy and a second substituent； -C(=N-O-R 8 )-C 1-4 alkyl； R 7 ； or -X 3 -R 7 ； R 4 is halo, hydroxy, C 1-6 alkyl, C 3-7 cycloalkyl, C 1-6 alkyloxy, cyano, nitro, polyhaloC 1-6 alkyl, polyhatoC 1-6 alkyloxy, aminocarbonyl, C 1-6 alkyloxycarbonyl, C 1-6 alkylcarbonyl, formyl, amino, mono- or di(C 1-4 alkyl)amino； their use as a medicine, their processes for preparation and pharmaceutical compositions comprising them.
